Ragnar Nortvedt

Prof. Dr. Ragnar Nortvedt

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Aquaculture
Verified
Journal Article
Closed access
EGEndre Grimsbø
Endre Grimsbø
Ragnar NortvedtRagnar Nortvedt
Ragnar Nortvedt
BHBjørn Tore Hjertaker
Bjørn Tore Hjertaker
EHErling Hammer
Erling Hammer
BRBjorn Roth
Bjorn Roth

13 August 2025 in Fishes
Verified
Journal Article
Open access
PDF file
Ragnar NortvedtRagnar Nortvedt
Ragnar Nortvedt
EDErik Dahl-Paulsen
Erik Dahl-Paulsen
LBLaura Patricia Apablaza Bizama
Laura Patricia Apablaza Bizama
AJAmritha Johny
Amritha Johny
ESERIK SLINDE
ERIK SLINDE
A new polypeptide vaccine towards salmon lice (Lepeophtheirus salmonis) was given to experimental groups of 2 × 8000 Atlantic salmon parr (Salmo salar L.), following the vaccination of a total of 4 × 8000 parr with a common set of vaccines used in Norwegian aquaculture to prevent infestation in salmon growing at sea. The remaining 2 × 8000 salmon served as control. The trial was conducted at a sea farm research facility at Knappen-Solheim in Masfjorden, Norway. Natural infestation with sea lice were staged and counted once a week from January–December 2023. The infestation was never above two mature female lice per salmon, the maximum limit set specifically for the present trial by the Norwegian Food Safety Authorities, thus delousing with chemicals or other methods was avoided. Mortality, growth, feed consumption, sexual maturation, slaughter quality, and welfare quality parameters were not significantly different between vaccinated and control salmon. The effect size showed a moderate positive difference of 0.07 mature female salmon lice per salmon in favor of the vaccinated groups from a fish size above 600 g in May until November. All fish were slaughtered and marketed at a size of 5.8 kg (>83% superior quality).

28 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Ragnar NortvedtRagnar Nortvedt
Ragnar Nortvedt
EDErik Dahl-Paulsen
Erik Dahl-Paulsen
LBLaura Patricia Apablaza Bizama
Laura Patricia Apablaza Bizama
AJAmritha Johny
Amritha Johny
ESERIK SLINDE
ERIK SLINDE
A new polypeptide vaccine towards salmon lice (Lepeophtheirus salmonis) was given to experimental groups of 2 x 8000 Atlantic salmon parr (Salmo salar L.), following the vaccination of a total of 4 x 8000 parr with a common set of vaccines used in Norwegian aquaculture to prevent infection in salmon growing at sea. The remaining 2 x 8000 salmon served as control. The trial was conducted at a sea farm research facility at Knappen-Solheim in Masfjorden, Norway. Natural infection with sea lice were staged and counted once a week from January – December 2023. The infection was never above 2 mature female lice per salmon, maximum limit set specifically for the present trial by the Norwegian Food Safety Authorities, thus delousing with chemicals or other methods was avoided. Mortality, growth, sexual maturation, slaughter quality and welfare quality parameters were not significantly different between vaccinated and control salmon. The vaccine had a minor positive effect on salmon lice development. All fish were slaughtered and marketed at a size of 5.8 Kg (> 83 % Superior quality).